Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Processa Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Processa Pharmaceuticals's regulatory disclosures and financial reporting.
Processa Pharmaceuticals, Inc. granted Chief Executive Officer George K. Ng 9,384 Restricted Stock Units on July 26, 2026. Each RSU equals one common share, vested immediately, with settlement deferred until termination, six months after grant, a change of control, or death.
After this award, Ng directly holds 21,224 RSUs, stock options for 30,720 shares at an exercise price of $4.96 per share, and additional direct and indirect common stock holdings; all reported share amounts reflect a 1-for-25 reverse stock split effected on December 17, 2025.
Neal James R reported acquisition or exercise transactions in this Form 4 filing.
Processa Pharmaceuticals, Inc. director Neal James R received a grant of 62,221 Restricted Stock Units (RSUs) on July 26, 2026, each representing one share of common stock. The RSUs vested upon grant but will be distributed only upon termination, six months after grant, a change of control, or death. Following this award, he holds 67,470 RSUs, stock options for 12,000 shares at $4.96 vesting over three years, and 1,021 common shares, all on a direct-ownership basis. Reported amounts reflect a 1-for-25 reverse stock split effective December 17, 2025.
Processa Pharmaceuticals, Inc. officer Patrick Lin received a grant of 8,450 Restricted Stock Units on 2026-07-26. Each RSU equals one share of common stock, vesting upon grant but distributed only at the earlier of termination, six months after grant, a change of control, or death. Following this award, he holds 11,389 RSUs, stock options over 8,160 shares at an exercise price of $4.9600 that vest over three years, and common stock holdings of 13,113 shares directly plus 1,740 shares indirectly through the Lin Family Trust. These amounts reflect a 1-for-25 reverse stock split effective December 17, 2025, and were not reported as made under a Rule 10b5-1 trading plan.
Processa Pharmaceuticals, Inc. reported that Chief Administrative Officer Wendy Guy received a grant of 9,450 Restricted Stock Units on 2026-07-26, each representing one share of common stock. These RSUs vested on grant but will be delivered in shares at the earlier of termination, six months after grant, a change of control, or death.
After this award, Guy holds 11,669 RSUs directly, stock options for 6,000 shares at an exercise price of $4.9600 vesting over three years, 14,394 shares of common stock directly, and 333 shares indirectly through CorLyst, LLC.
Baluch Khoso reported acquisition or exercise transactions in this Form 4 filing.
Processa Pharmaceuticals, Inc. director Baluch Khoso received a grant of 33,500 Restricted Stock Units on 26 July 2026, each representing one share of common stock. The RSUs vested immediately but will be distributed only upon termination, six months after grant, a change of control, or death. Following this award, Khoso holds 38,749 RSUs, 12,000 stock options to buy common shares at $4.96, and 2,528 common shares directly, all reflecting a 1-for-25 reverse stock split completed in December 2025.
Processa Pharmaceuticals insider activity: Chief Administrative Officer Guy Wendy bought 2,436 shares of common stock in an open-market purchase at $1.93 per share. After this trade, she holds 14,394 shares directly and 333 shares indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. executive Patrick Lin, Chief Business-Strategy Officer, bought additional common stock in the company. On June 30, 2026, he made an open-market purchase of 2,106 shares at $1.93 per share.
After this transaction, Lin directly holds 13,113 common shares. The filing also lists an indirect holding of 1,740 shares registered under the Lin Family Trust dated February 4, 2024, giving investors a clearer view of both his direct and trust-related ownership.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought 3,057 shares of Common Stock in an open-market purchase at $1.93 per share on July 1, 2026. After this trade, he directly owns 15,492 shares, plus additional indirect holdings through related entities.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of 3,277 shares of Common Stock at $1.93 per share. After this transaction, he directly owns 16,689 shares. This filing reflects a relatively small insider buy by a senior executive.
Processa Pharmaceuticals, Inc. director and officer David Young bought additional common stock in an open-market transaction. On June 30, 2026, he purchased 2,531 shares at $1.93 per share, bringing his direct holdings to 21,729 shares of common stock.
He also reports indirect ownership of common stock through several entities as of that date: 1,009 shares held by CorLyst, LLC, 432 shares held by Family Entities, and 1,242 shares held by the Young-Plaisance Revocable Trust.